News

AliveDx recently partnered with the Great Place To Work organization to support our journey toward becoming an exceptional workplace for all our employees. Our goal is to foster a sense of belonging, instill pride in the work we do, and

We are excited to announce that two AliveDx abstracts are now available publicly in the Abstract Book of the European Congress of Rheumatology (EULAR 2024), an international event that will take place in Vienna, Austria from 12-15 June 2024. The

We are pleased to announce that our Eysins site in Switzerland has successfully passed the annual ISO 14001 Surveillance Audit. This site, first certified in 2022, continues to demonstrate our commitment to environmental management and sustainability. The ISO 14001 is

AliveDx Suisse S.A. and Palex Medical S.A.U. have signed a distribution agreement, which will enable Palex to distribute the MosaiQ® solution in Spain. The distribution agreement takes effect immediately. This partnership reaffirms AliveDx’s commitment to expanding its geographical presence and

AliveDx Suisse S.A. and Medical Development Medical Devices WLL have signed a distribution agreement, which will enable Medical Development Medical Devices to distribute the MosaiQ® solution in the Kingdom of Bahrain. The distribution agreement takes effect immediately. AliveDx is dedicated

AliveDx Suisse S.A. and Lavichem Joint Stock Company have signed a distribution agreement, which will enable Lavichem to distribute the MosaiQ® solution in North Vietnam. The distribution agreement takes effect immediately. AliveDx is committed to broadening its reach and presence

AliveDx Suisse S.A. and Medlinks Consulting Joint Stock Company have signed a distribution agreement, which will enable Medlinks to distribute the MosaiQ® solution in South Vietnam. The distribution agreement takes effect immediately. AliveDx is dedicated to expanding its reach and

We are excited to announce that our abstract titled “Performance characteristics of a novel, fully automated immunoassay microarray for the qualitative serological detection of specific IgE directed against Bet v 1” has been accepted by the European Congress of Immunology

AliveDx Suisse S.A. and Patho Solutions Malaysia Sdn. Bhd. have signed a distribution agreement, which will enable Patho Solutions Malaysia to distribute the MosaiQ® solution in Malaysia. The distribution agreement takes effect immediately. AliveDx is dedicated to expanding its reach

AliveDx Suisse S.A. and Everlight Biotech Co. Ltd. have signed a distribution agreement, which will enable Everlight Biotech Co. Ltd. to distribute the MosaiQ® solution in Taiwan. The distribution agreement takes effect immediately. AliveDx is dedicated to expanding its reach